-
Start Preamble
AGENCY:
Agency for Healthcare Research and Quality, HHS.
ACTION:
Notice.
SUMMARY:
In accordance with section 10(a)(2) of the Federal Advisory Committee Act, announcement is made of an Agency for Healthcare Research and Quality (AHRQ) Special Emphasis Panel (SEP) meeting on AHRQ-HS-20-001, “Improving Management of Opioids and Opioid Use Disorder (OUD) in Older Adults (R18).” This SEP meeting will be closed to the public.
DATES:
May 29, 2020.
ADDRESSES:
Agency for Healthcare Research and Quality (Virtual Review), 5600 Fishers Lane, Rockville, Maryland 20850.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Anyone wishing to obtain a roster of members, agenda or minutes of the non-confidential portions of this meeting should contact: Jenny Griffith, Acting Committee Management Officer, Office of Extramural Research, Education and Priority Populations, AHRQ, 5600 Fishers Lane, Rockville, Maryland 20850, Telephone: (301) 427-1557.
Agenda items for this meeting are subject to change as priorities dictate.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by the Agency for Healthcare Research and Quality (AHRQ), and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularly-scheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise.
The SEP meeting referenced above will be closed to the public in accordance with the provisions set forth in 5 U.S.C. App. 2, section 10(d), 5 U.S.C. 552b(c)(4), and 5 U.S.C. 552b(c)(6). Grant applications for the AHRQ-HS-20-001, “Improving Management of Opioids and Opioid Use Disorder (OUD) in Older Adults (R18)” is to be reviewed and discussed at this meeting. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Start SignatureDated: May 1, 2020.
Virginia L. Mackay-Smith,
Associate Director.
[FR Doc. 2020-09723 Filed 5-6-20; 8:45 am]
BILLING CODE 4160-90-P
Document Information
- Published:
- 05/07/2020
- Department:
- Agency for Healthcare Research and Quality
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2020-09723
- Dates:
- May 29, 2020.
- Pages:
- 27226-27226 (1 pages)
- PDF File:
- 2020-09723.pdf
- Supporting Documents:
- » Supplemental Evidence and Data Request: Transitions of Care from Pediatric to Adult Services for Children with Special Healthcare Needs
- » Meetings
- » Supplemental Evidence and Data Request: Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea in Medicare Eligible Patients
- » Agency Information Collection Activities; Proposals, Submissions, and Approvals
- » Request for Nominations: Members of the National Advisory Council for Healthcare Research and Quality
- » Supplemental Evidence and Data Request: Safety of Vaccines Used for Routine Immunization in the United States
- » Agency Information Collection Activities; Proposals, Submissions, and Approvals
- » Supplemental Evidence and Data Request: Platelet-Rich Plasma for Wound Care in the Medicare Population
- » Agency Information Collection Activities; Proposals, Submissions, and Approvals
- » Meetings: National Advisory Council for Healthcare Research and Quality